Results 81 to 90 of about 4,214,171 (152)

New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer

International audienceMetastatic prostate cancer is a frequent and fatal disease. Targeted radionuclide therapy (TRT) has become a readily available therapeutic option since the approval of [ 177 Lu]Lu-PSMA-617.
Deshayes, Emmanuel, Hébert, Kévin, Bodin-Cufi, Paul, Fersing, Cyril   +3 more
core   +1 more source

Investigating the significance of SPECT/CT-SUV for monitoring 177Lu-PSMA-targeted radionuclide therapy: a systematic review

BMC Medical Imaging
Background Quantitative molecular imaging via single-photon emission computed tomography-derived standardised uptake value (SPECT/CT-SUV) is used to assess the response of metastatic castration-resistant prostate cancer (mCRPC) patients to targeted ...
Tahani O. Alkahtani
doaj   +1 more source

Camouflaged membrane-bridged radionuclide/Mn single-atom enzymes target lipid metabolism disruption to evoke antitumor immunity

Military Medical Research
Background Lipid metabolic reprogramming has been increasingly recognized as a key factor contributing to tumor immune evasion, therapeutic resistance, and plasticity, which collectively compromise the efficacy of targeted radionuclide therapy (TRT ...
Meng-Die Yang, Chun-Yan Zhu, Gang Yang, Xiao-Yi Zhang, Yi Zhu, Miao Chen, Jia-Jia Zhang, Ling Bai, Shan-Shan Qin, Chao Ma, Fei Yu, Kun Zhang   +11 more
doaj   +1 more source

Radiopharmaceuticals and theranostics: reshaping cancer diagnosis and therapy with targeted radionuclides. [PDF]

RSC Adv
Zulfiqar H, Waqas M, Ali I.
europepmc   +1 more source

Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes. [PDF]

Clin Cancer Res
Nonnekens J, Byers LA, Chauhan A, George DJ, Hicks RJ, Weber WA.   +5 more
europepmc   +1 more source

Combined radioligand therapy and immunotherapy for cancer: research advances and translational challenges. [PDF]

Front Pharmacol
Wang S, Tang S, Tang S, Wang C, Wang J, Yang Y, Yang Y, Liu C, Fu J, Zhou H.   +9 more
europepmc   +1 more source

Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects. [PDF]

Eur J Nucl Med Mol Imaging
Kurniawan A, Cano LH, Mayenco ND, Unnikrishnan S, Elsinga PH, Antunes IF, de Vries EFJ, Cornelissen B.   +7 more
europepmc   +1 more source

Influence of immune checkpoint inhibitor target and timing on combination treatment with antibody-based β-emitting targeted radionuclide therapy across tumor immunogenicity profiles. [PDF]

Front Immunol
Kleinendorst SC, Oosterwijk E, Konijnenberg M, Boswinkel M, Gloudemans M, Wenker STM, Muselaers S, Mulders P, Maffa L, O'Hara MF, Wheatcroft MP, Twumasi-Boateng K, Heskamp S.   +12 more
europepmc   +1 more source

In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models. [PDF]

Cancer Immunol Res
Debnath T, Jin WJ, Patel RB, Carlson PM, Rahman MM, Berg TJ, Kerr CP, Schwartz RW, Wang Y, Hyun M, Ong IM, Weichert JP, Hernandez R, Sondel PM, Morris ZS.   +14 more
europepmc   +1 more source

Lutetium-177 radiopharmaceuticals in cancer care: progress and challenges. [PDF]

Front Pharmacol
Shi W, Zhang L, Feng X, Liu J, Li X, Dong X, Li-Ann Wong A, Chen X, Wang L, Goh BC.   +9 more
europepmc   +1 more source